All Stacks
Intermediate12–24 weeks
The Fat Loss & Vascularity Stack
Triple-receptor GLP-1 agonism + GH axis for maximum fat oxidation
24.2%
Body weight reduction
Combining a next-generation GLP-1/GIP/glucagon tri-agonist with CJC-1295/Ipamorelin creates a metabolic environment optimized for fat oxidation while preserving lean tissue. Retatrutide produced the highest pharmacological fat loss ever documented in a Phase 2 trial.
Stack Compounds
Documented Outcomes
Up to 24.2% total body weight reduction (NEJM Phase 2)
Preserved lean muscle mass during deficit
Improved insulin sensitivity and lipid profile
BPC-157 supports gut barrier integrity during caloric restriction
Other Protocols
Source Every Compound from Apollo Peptide Sciences
Every compound in this stack — independently third-party tested, premium grade, with CoA documentation.
Shop Apollo Peptide Sciences